In recent years, the potential of MDMA as a treatment for Post-Traumatic Stress Disorder has generated significant interest within the medical community. The drug, commonly known as ecstasy, has moved beyond its controversial recreational use to become a promising candidate for therapeutic purposes. However, the path to its approval has encountered significant hurdles. Recently, the FDA rejected Lykos Therapeutics' application for MDMA therapy, leaving many to wonder about the future of this approach.

Read the full article.

About the author:
Madeline Campbell, Ph.D.